Emerging therapies expected to reshape endometrial cancer market landscape

7 November 2025

The global endometrial cancer market is on course for steady expansion, projected to reach nearly $39 billion by 2030. Growth is being fueled by rising incidence rates linked to aging populations, obesity, and metabolic conditions, alongside expanding use of targeted and immuno-oncology therapies in key regions, particularly the USA.

The latest DelveInsight analysis shows that around 68,000 American women were diagnosed with the disease in 2024, with the USA representing the largest share of the global market. While surgery remains the mainstay of treatment, newer agents such as Keytruda (pembrolizumab) have transformed outcomes in advanced disease since their first approval in 2021.

Merck & Co (NYSE: MRK), which generated roughly $29.5 billion in 2024 sales from Keytruda, leads the field, followed by companies including Karyopharm Therapeutics (Nasdaq: KPTI), AstraZeneca (LSE: AZN), Daiichi Sankyo (TSE: 4568), Faeth Therapeutics, Roche (ROG: SIX), Iovance Biotherapeutics (Nasdaq: IOVA), and GSK (LSE: GSK).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK